Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NASDAQ:PIRS
- CUSIP: N/A
- Web: www.pieris.com
- Market Cap: $173.11 million
- Outstanding Shares: 43,063,000
- 50 Day Moving Avg: $2.96
- 200 Day Moving Avg: $2.19
- 52 Week Range: $1.30 - $4.28
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.28
- P/E Growth: 0.00
- Annual Revenue: $5.93 million
- Price / Sales: 29.19
- Book Value: $0.42 per share
- Price / Book: 9.57
- EBIDTA: ($26,030,000.00)
- Net Margins: -364.96%
- Return on Equity: -60.26%
- Return on Assets: -47.47%
- Current Ratio: 4.13%
- Quick Ratio: 4.13%
- Average Volume: 1.04 million shs.
- Beta: 1.91
- Short Ratio: 3.39
Frequently Asked Questions for Pieris Pharmaceuticals (NASDAQ:PIRS)
What is Pieris Pharmaceuticals' stock symbol?
Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."
How were Pieris Pharmaceuticals' earnings last quarter?
Pieris Pharmaceuticals Inc (NASDAQ:PIRS) announced its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.19) EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.16 by $0.35. The company earned $1.34 million during the quarter, compared to analyst estimates of $32.30 million. Pieris Pharmaceuticals had a negative net margin of 364.96% and a negative return on equity of 60.26%. View Pieris Pharmaceuticals' Earnings History.
Where is Pieris Pharmaceuticals' stock going? Where will Pieris Pharmaceuticals' stock price be in 2017?
2 brokers have issued 1-year price objectives for Pieris Pharmaceuticals' shares. Their predictions range from $6.00 to $9.00. On average, they anticipate Pieris Pharmaceuticals' share price to reach $7.50 in the next year. View Analyst Ratings for Pieris Pharmaceuticals.
Who are some of Pieris Pharmaceuticals' key competitors?
Some companies that are related to Pieris Pharmaceuticals include ChemoCentryx (CCXI), Corbus Pharmaceuticals Holdings (CRBP), Nantkwest (NK), GlycoMimetics (GLYC), Concert Pharmaceuticals (CNCE), Edge Therapeutics (EDGE), Ocular Therapeutix (OCUL), XBiotech (XBIT), Novavax (NVAX), Ignyta (RXDX), Veracyte (VCYT), SIGA Technologies (SIGA), Dynavax Technologies (DVAX), Nabriva Therapeutics AG - (NBRV), Compugen (CGEN), Minerva Neurosciences (NERV), Ardelyx (ARDX) and Sinovac Biotech (SVA).
Who owns Pieris Pharmaceuticals stock?
Pieris Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Tekla Capital Management LLC (9.15%), Omega Fund Management LLC (3.94%), Sphera Funds Management LTD. (2.32%), Renaissance Technologies LLC (0.59%), Morgan Stanley (0.45%) and Creative Planning (0.14%). Company insiders that own Pieris Pharmaceuticals stock include Darlene M Deptula-Hicks, Louis Matis and Stephen S Yoder. View Institutional Ownership Trends for Pieris Pharmaceuticals.
Who sold Pieris Pharmaceuticals stock? Who is selling Pieris Pharmaceuticals stock?
Who bought Pieris Pharmaceuticals stock? Who is buying Pieris Pharmaceuticals stock?
Pieris Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Sphera Funds Management LTD., Creative Planning and Morgan Stanley. Company insiders that have bought Pieris Pharmaceuticals stock in the last two years include Darlene M Deptula-Hicks, Louis Matis and Stephen S Yoder. View Insider Buying and Selling for Pieris Pharmaceuticals.
How do I buy Pieris Pharmaceuticals stock?
Shares of Pieris Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Pieris Pharmaceuticals stock cost?
One share of Pieris Pharmaceuticals stock can currently be purchased for approximately $4.02.
Earnings History for Pieris Pharmaceuticals (NASDAQ:PIRS)Earnings History by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/10/2017||Q1 2017||$0.16||($0.19)||$32.30 million||$1.34 million||View||N/A|
|8/10/2016||Q216||($0.15)||($0.14)||$1.08 million||$1.07 million||View||N/A|
|5/11/2016||Q116||($0.12)||($0.10)||$6.40 million||$1.25 million||View||N/A|
|3/23/2016||Q415||($0.12)||($0.07)||$3.27 million||$2.14 million||View||N/A|
|11/11/2015||Q315||($0.11)||($0.10)||$0.23 million||$0.42 million||View||N/A|
|8/12/2015||Q215||($0.14)||($0.12)||$0.25 million||$0.16 million||View||N/A|
Earnings Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)
2017 EPS Consensus Estimate: $0.05
2018 EPS Consensus Estimate: ($0.83)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Pieris Pharmaceuticals (NASDAQ:PIRS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Pieris Pharmaceuticals (NASDAQ:PIRS)
Insider Ownership Percentage: 2.43%Insider Trades by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)
Institutional Ownership Percentage: 47.58%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/14/2016||Louis Matis||SVP||Buy||10,000||$1.70||$17,000.00|| |
|6/13/2016||Darlene M Deptula-Hicks||CFO||Buy||5,000||$1.66||$8,300.00|| |
|6/13/2016||Stephen S Yoder||CEO||Buy||6,000||$1.68||$10,080.00|| |
Headline Trends for Pieris Pharmaceuticals (NASDAQ:PIRS)
Latest Headlines for Pieris Pharmaceuticals (NASDAQ:PIRS)
|Pieris Pharmaceuticals Appoints James Geraghty to its Board of Directors|
finance.yahoo.com - May 22 at 6:24 PM
|Pieris Pharmaceuticals Inc (PIRS) Expected to Earn Q1 2018 Earnings of ($0.22) Per Share|
www.americanbankingnews.com - May 15 at 9:06 AM
|Pieris Pharmaceuticals Inc (PIRS) Issues Earnings Results|
www.americanbankingnews.com - May 11 at 7:18 PM
|Pieris Pharmaceuticals Reports Financial Results for the First Quarter Ended March 31, 2017 and Provides Corporate Update|
finance.yahoo.com - May 10 at 7:28 PM
|Pieris Pharmaceuticals reports 1Q loss|
finance.yahoo.com - May 10 at 7:28 PM
|Pieris Pharmaceuticals (PIRS) Earns Daily Coverage Optimism Score of 0.31|
www.americanbankingnews.com - May 8 at 11:45 PM
|Pieris Pharmaceuticals Inc (PIRS) Rating Increased to C- at TheStreet|
www.americanbankingnews.com - May 6 at 11:52 PM
|Gainers & Losers Of May 3: PIRS, MYGN, XENT, RXDX, SPPI...|
www.finanznachrichten.de - May 5 at 12:26 AM
|Pieris Pharmaceuticals (PIRS) Earning Somewhat Favorable News Coverage, Study Shows|
www.americanbankingnews.com - May 4 at 11:17 AM
|Zacks: Pieris Pharmaceuticals Inc (PIRS) Given Consensus Rating of "Strong Buy" by Brokerages|
www.americanbankingnews.com - May 4 at 8:12 AM
|Pieris Pharmaceuticals to Host First Quarter 2017 Investor Call and Corporate Update on May 11, 2017|
finance.yahoo.com - May 1 at 11:34 AM
|Pieris Pharmaceuticals (PIRS) Getting Somewhat Positive Media Coverage, Study Shows|
www.americanbankingnews.com - April 28 at 11:38 PM
|Pieris Pharmaceuticals Inc (PIRS) PT Set at $9.00 by Oppenheimer Holdings Inc.|
www.americanbankingnews.com - April 18 at 7:48 AM
|Pieris Pharmaceuticals Inc Expected to Post Q1 2017 Earnings of $0.52 Per Share (PIRS)|
www.americanbankingnews.com - April 14 at 8:12 AM
|Oppenheimer Holdings Inc. Analysts Give Pieris Pharmaceuticals Inc (PIRS) a $9.00 Price Target|
www.americanbankingnews.com - April 13 at 6:14 PM
|Pieris Pharmaceuticals (PIRS) Given Coverage Optimism Rating of -0.12|
www.americanbankingnews.com - April 13 at 12:48 PM
|Pieris Pharmaceuticals Presents IND-enabling Data for Bispecific Immuno-Oncology Drug Candidate, PRS-343, in Poster Session at the 2017 Meeting of the American Association for Cancer Research (AACR)|
finance.yahoo.com - April 7 at 11:55 AM
| Pieris Pharmaceuticals Inc (PIRS) Given $8.50 Average Target Price by Analysts|
www.americanbankingnews.com - April 4 at 12:46 AM
|PIERIS PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report|
biz.yahoo.com - March 30 at 7:31 PM
|Pieris Pharmaceuticals Inc. (PIRS) CEO Stephen Yoder on Q4 2016 Results - Earnings Call Transcript|
seekingalpha.com - March 23 at 7:42 PM
|PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements|
biz.yahoo.com - March 23 at 8:42 AM
|Pieris Pharmaceuticals (PIRS) Presents At Oppenheimer 27th Annual Healthcare Conference|
seekingalpha.com - March 22 at 7:13 PM
|Pieris Pharmaceuticals to Host Full-Year 2016 Investor Call And Corporate Update on March 23, 2017|
finance.yahoo.com - March 15 at 9:24 AM
|Pieris Pharmaceuticals to Present at Oppenheimer's 27th Annual Healthcare Conference, Wednesday, March 22nd at 11:30 am EDT|
finance.yahoo.com - March 14 at 10:15 AM
|Pieris Pharmaceuticals to Present at the 29th Annual Roth Conference Monday, March 13th at 2:00 pm PST|
finance.yahoo.com - March 7 at 9:44 AM
|Pieris Pharmaceuticals Announces Presentation of IND-enabling Data for Bispecific Immuno-Oncology Drug Candidate, PRS-343, at the 2017 Meeting of the American Association for Cancer Research (AACR)|
finance.yahoo.com - March 6 at 6:37 PM
|Pieris Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference on March 6th at 4:40 pm EST|
finance.yahoo.com - March 1 at 9:32 AM
|Pieris Pharma (PIRS) Grants Exclusive Option for PRS-080 in Japan to ASKA Pharmaceutical|
www.streetinsider.com - February 27 at 9:49 AM
|Pieris Signs 1st Partnership for Anemia Drug PRS-080, Granting Exclusive Option in Japan to ASKA Pharmaceutical|
us.rd.yahoo.com - February 27 at 9:49 AM
|Pieris Pharmaceuticals' stock soars after exclusive license deal with Japan's ASKA|
www.marketwatch.com - February 27 at 9:49 AM
|PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Change in Directors|
us.rd.yahoo.com - February 8 at 8:12 PM
|Pieris Pharmaceuticals to Present at the Bio CEO Investor Conference on February 13th at 1:30 pm EST|
finance.yahoo.com - February 8 at 8:12 PM
|Pieris Pharma (PIRS) CFO to Resign - StreetInsider.com|
www.streetinsider.com - February 8 at 2:04 AM
|Pieris Pharma (PIRS) CFO to Resign|
www.streetinsider.com - February 7 at 9:02 PM
|Pieris Announces Management Transition|
us.rd.yahoo.com - February 7 at 9:02 PM
|PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits|
us.rd.yahoo.com - January 9 at 7:55 PM
|7:48 am Pieris Pharmaceuticals provides 2017 milestones in slide presentation|
us.rd.yahoo.com - January 9 at 7:55 PM
Pieris Pharmaceuticals (PIRS) Chart for Wednesday, May, 24, 2017